Oct 29, 2026 7:00 am EDT Kiora Pharmaceuticals In-Licenses Late-Stage, Oral Neuroprotective Calpain Inhibitor for Central Retinal Artery Occlusion (CRAO) with Planned Expansion into NAION; Asset Completed Phase 3 Clinical Trial in CRAO in Japan
Sep 8, 2026 7:00 am EDT Kiora Pharmaceuticals Appoints Keith J. Lane as Executive Vice President of Global Clinical Development and Regulatory Affairs
Aug 19, 2026 7:00 am EDT Kiora Pharmaceuticals Licenses South Korean Ophthalmic Development and Commercialization Rights for KIO-301 to Chong Kun Dang Pharmaceutical Corporation
Aug 7, 2026 7:00 am EDT Kiora Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Jul 2, 2026 7:00 am EDT Kiora Pharmaceuticals to Participate in Piper Sandler Virtual Ophthalmology Symposium
Jun 18, 2026 7:00 am EDT Kiora Pharmaceuticals Reports its Ion Channel Modulator, KIO-300, Suppressed Seizure Activity in Preclinical Epilepsy Model
May 8, 2026 7:00 am EDT Kiora Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Corporate Update
Apr 14, 2026 7:00 am EDT Kiora's Phase 1 ABACUS Study of KIO-301 in Retinitis Pigmentosa Published in Nature Medicine; Phase 2 Trial Underway
Apr 7, 2026 7:00 am EDT Kiora Pharmaceuticals Announces Private Placement for Up to $24 Million Led by Perceptive Advisors